Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRENA: Elacestrant in ER+/HER2- Advanced Breast Cancer
NCT07753954Phase 2Not yet recruiting
- Sponsor
- Institut Jules Bordet
- Start
- Sep 2026
- Primary completion
- Aug 2031
01
Overview
Phase 2, open-label, single-arm trial of elacestrant in breast cancer, sponsored by Institut Jules Bordet. Primary endpoint: Progression-Free Survival at 6 months. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
elacestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07753954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07753954.